Education
About Us
Working with TipRanks
Follow Us
BioMarin Pharmaceutical (BMRN)
NASDAQ:BMRN
BMRN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$52.93 - $78.00
Previous CloseN/A
Volume465.01K
Average Volume (3M)2.28M
Market Cap
$10.39B
Enterprise Value$10.01B
Total Cash (Recent Filing)$1.43B
Total Debt (Recent Filing)$603.87M
Price to Earnings (P/E)16.0
Beta0.43
Next Earnings
Oct 22, 2025EPS Estimate
0.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.23
Shares Outstanding192,014,600
10 Day Avg. Volume1,775,931
30 Day Avg. Volume2,278,489
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)2.21
Price to Sales (P/S)4.38
P/FCF Ratio26.27
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue3.27
Enterprise Value/Gross Profit4.11
Enterprise Value/Ebitda11.19
Forecast
1Y Price Target
$98.59Price Target Upside85.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering24
Bulls Say, Bears Say
Bulls Say
Market ExpansionPalynziq expansion to adolescents can increase market share due to lack of Phe-restricted diet requirement, clear effect in BH4-unresponsive patients, and BMRN's strong establishment in PKU.
Regulatory ApprovalsBMRN presented detailed data from the Ph3 study of Palynziq in adolescent patients, which showed strong efficacy that should support regulatory approvals for label expansion in 2026.
Revenue GrowthPalynziq label expansion into adolescents can contribute to revenue growth, positioning BMRN favorably in the market.
Bears Say
CompetitionVOXZOGO accounts for nearly 30% of revenues and faces rising competitive pressure from orals with similar efficacy and superior convenience, limiting upside potential.
Product ChallengesVOXZOGO’s trajectory faces a looming challenge from more convenient oral drugs with comparable efficacy.
Stock PerformanceBMRN shares fell nearly 20% on positive competitor TransCon CNP data, underscoring that VOXZOGO competition—not incremental pipeline wins—drives the stock.
BioMarin Pharmaceutical News
BMRN FAQ
What was BioMarin Pharmaceutical’s price range in the past 12 months?
BioMarin Pharmaceutical lowest stock price was $52.93 and its highest was $78.00 in the past 12 months.
What is BioMarin Pharmaceutical’s market cap?
BioMarin Pharmaceutical’s market cap is $10.39B.
When is BioMarin Pharmaceutical’s upcoming earnings report date?
BioMarin Pharmaceutical’s upcoming earnings report date is Oct 22, 2025 which is in 36 days.
How were BioMarin Pharmaceutical’s earnings last quarter?
BioMarin Pharmaceutical released its earnings results on Aug 04, 2025. The company reported $1.23 earnings per share for the quarter, beating the consensus estimate of $0.861 by $0.369.
Is BioMarin Pharmaceutical overvalued?
According to Wall Street analysts BioMarin Pharmaceutical’s price is currently Undervalued.
Does BioMarin Pharmaceutical pay dividends?
BioMarin Pharmaceutical does not currently pay dividends.
What is BioMarin Pharmaceutical’s EPS estimate?
BioMarin Pharmaceutical’s EPS estimate is 0.88.
How many shares outstanding does BioMarin Pharmaceutical have?
BioMarin Pharmaceutical has 192,014,600 shares outstanding.
What happened to BioMarin Pharmaceutical’s price movement after its last earnings report?
BioMarin Pharmaceutical reported an EPS of $1.23 in its last earnings report, beating expectations of $0.861. Following the earnings report the stock price went up 2.686%.
Which hedge fund is a major shareholder of BioMarin Pharmaceutical?
Currently, no hedge funds are holding shares in BMRN
BioMarin Pharmaceutical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$98.59 (85.53% Upside)
$98.59 (85.53% Upside)
Blogger Sentiment
Bullish
BMRN Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 3.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 6.7%
Last 30 Days ▲ 6.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.89%
12-Months-Change
Fundamentals
Return on Equity
11.62%
Trailing 12-Months
Asset Growth
5.51%
Trailing 12-Months
Company Description
BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
BMRN Company Deck
BMRN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
BioMarin Pharmaceuticals reported strong revenue growth, successful acquisition of Inozyme, and significant progress in their pipeline, which were slightly offset by increased operating expenses and adjusted revenue guidance for VOXZOGO.View all BMRN earnings summariesBMRN Revenue Breakdown
28.98% VIMIZIM
19.42% VOXZOGO
17.37% NAGLAZYME
12.56% PALYNZIQ
21.66% Other
BMRN Stock 12 Month Forecast
Average Price Target
$98.59
▲(85.53% Upside)
Technical Analysis
Ownership Overview
0.54% Insiders
30.34% Mutual Funds
36.47% Other Institutional Investors
10.23% Public Companies and Individual Investors